Myasthenia Gravis Market Dynamics, Overview, Share and SWOT Analysis | Forecast to 2027
Myasthenia
Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis,
Generalized Myasthenia Gravis, Transient Myasthenia Gravis and Others),
(Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers
and Academic and Research Organizations) and By Region-Global Forecast Till
2027
Myasthenia Gravis Market Highlights
The
latest study conducted by Market Research Future (MRFR) reveals the Global Myasthenia Gravis (MG)
is set to witness 9.61% CAGR during the assessment period (2018-2023) and
surpass a valuation of USD 3,000 Mn.
Factors such as increased prevalence rate, investment in R&D and
advances in healthcare are likely to support the growth of the market. In
recent years, a sharp rise in MG and related incidences has been noticed. In
advanced countries, a greater level of awareness prevails, which is favoring
the market’s growth. It is understood that early diagnosis and treatment can
reduce the impact of the condition to a significant extent, however outcomes
may vary from case to case.
Advances
in technology has resulted in development of therapeutics that are more
effective as compared to traditional medicines. At the same time, increased
level of awareness among patients and government support in product research
& development is expected to create market opportunities in forthcoming
years. Nonetheless, high cost of treatment is currently viewed as the primary
restraint for the markets
Request
Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/7267
Segmental Analysis
The
report includes a segmental analysis of the market, which covers disease type,
end-user, diagnosis and treatment and region. By type, the market has been
segmented into congenital myasthenia gravis, transient myasthenia gravis,
ocular myasthenia gravis, generalized myasthenia gravis and others. The
generalized myasthenia gravis segment accounts for the dominant share of the
market. The segment currently stands at market valuation of USD 700 Mn and is
likely to reach USD 1526.66 Mn by 2023, reflecting a healthy CAGR. This
primarily owing to the widespread prevalence of generalized myasthenia gravis.
By diagnosis and treatment, the market has been into diagnosis and treatment.
Sub-segments of the diagnosis segment that are discussed in the report are electrodiagnostic
testing, imaging and Lab-based test. Sub-segments of the treatment segment
discussed in the report are plasmapheresis and intravenous immunoglobulin,
immunosuppressive drugs, thymectomy and cholinesterase inhibitors. The
treatment segment is expected to highly profitable over the next couple of
years. The segment currently accounts for nearly two-third share of the market
and expected to capture 9.52% CAGR during the forecast period. By end user, the
market has been segmented into academic and research organizations, diagnostic
centers and hospitals and clinics. The hospitals and clinics segment commands
the largest market share in terms of value.
Regional Analysis
The
regions that are covered in the report are Europe, Americas, Asia Pacific (APAC),
and the Middle East and Africa (MEA). Of these, Americas captured the largest
market share in terms of value. The region is likely to retain its dominance
over the review period. There are several factors that can be linked with the
region superior position, the prominent ones being existence of a world-class
healthcare system, particularly in countries such as the U.S. and Canada,
rising healthcare spending and availability of a wide rang of treatment
options. The region is followed by Europe and Asia Pacific respectively. The
market in Europe is currently valued at USD 675.12 Mn and expected to record a
steady growth over the review period. Meanwhile, Asia Pacific is expected to
post the highest CAGR over 2023. Presence of a massive patient pool and rising
geriatric population is driving the market’s growth in APAC. Additionally,
countries such as India and China are undergoing policy overhaul, to improve
the socio-economic elements. As a result, a number of sectors, including the
healthcare have witness tremendous transformation. Such changes are opening new
avenues for market players functioning in the region.
Myasthenia Gravis Market: Competitive
Landscape
Global
players mentioned in MRFR’s report include GE Healthcare, Novartis AG, Boston
Scientific Corporation, Grifols S.A., Koninklijke Philips N.V., Alexion
Pharmaceuticals, Inc. Valeant Pharmaceuticals International, Inc., Pfizer Inc.,
Medtronic Plc., Shire, CSL Behring and Baxter.
Browse Detailed TOC with
COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/myasthenia-gravis-market-7267
About
Market Research Future:
At Market Research Future
(MRFR), we enable our customers to unravel the complexity of various industries
through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
& Consulting Services. MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email:
sales@marketresearchfuture.com
Comments
Post a Comment